Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Liver Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Cervical Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Solid Tumors

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Colon Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Testicular Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: SCLC
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Esophageal Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Thyroid Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Ovarian Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Gastric Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

  • Details

ClinicalTrials.gov ID: NCT03668119
Diagnosis Type: NA
USOR Number: 16240

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Lymphomas

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (D8220R00004)

  • Details

ClinicalTrials.gov ID: NCT03816683
Diagnosis Type: NA
USOR Number: 18127

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)(20975)

  • Details

ClinicalTrials.gov ID: NCT04126733
Diagnosis Type: NA
USOR Number: 19096

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Colon Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)(20975)

  • Details

ClinicalTrials.gov ID: NCT04126733
Diagnosis Type: NA
USOR Number: 19096

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

  • Details

ClinicalTrials.gov ID: NCT03661320
Diagnosis Type: NA
USOR Number: 18095

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

  • Details

ClinicalTrials.gov ID: NCT03901339
Diagnosis Type: NA
USOR Number: 18282

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

2030 Mountain View Dr, Suite 210
Longmont, Colorado 80501
550.39 mi. away
P: (303) 684-1900

More Details View Practice Page

Pages